Skip to main content
SpringerLink
Log in

Risperidone injection to be priced at premium to oral formulation

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Risperidone injection to be priced at premium to oral formulation. Pharmacoecon. Outcomes News 437, 11 (2003). https://doi.org/10.1007/BF03277015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03277015

Keywords

Search

Navigation